Biofrontera Inc
NASDAQ:BFRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vestum AB (publ)
STO:VESTUM
|
SE |
|
A
|
Alkosign Ltd
BSE:543453
|
IN |
|
Good Spirits Hospitality Ltd
NZX:GSH
|
NZ |
|
Q
|
Qualcomm Inc
LSE:0QZ3
|
US |
|
Ibersol SGPS SA
LSE:0KJ7
|
PT |
|
Guangdong Goworld Co Ltd
SZSE:000823
|
CN |
|
Monte Carlo Fashions Ltd
NSE:MONTECARLO
|
IN |
Biofrontera Inc
Accounts Payable
Biofrontera Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biofrontera Inc
NASDAQ:BFRI
|
Accounts Payable
$6.7m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Payable
$12B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Payable
$3.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Payable
$5.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Payable
$4.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Payable
$5.4B
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
15%
|
|
Biofrontera Inc
Glance View
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.
See Also
What is Biofrontera Inc's Accounts Payable?
Accounts Payable
6.7m
USD
Based on the financial report for Dec 31, 2025, Biofrontera Inc's Accounts Payable amounts to 6.7m USD.
What is Biofrontera Inc's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
37%
Over the last year, the Accounts Payable growth was -7%. The average annual Accounts Payable growth rates for Biofrontera Inc have been 37% over the past three years .
